Cold-cough

Commercial

Portfolio-7447-for-WEB

NCE Pipeline

Discovery-7447-for-WEB

Research

Latest Annual Report

Vernalis-AR2013-CoverApr 01, 2014

2013 Results Download our latest report...        


Archive

Latest Presentation

ceoMay 1, 2015

Our latest presentation is available to view here...


Archive

Share Price

Share price:  78.25p
Change:  3.00 (3.99%)
As at:  28 August 2015 18:15:01
Volume:  192,021
LSE ID:  VER

Share price details

Latest News

Vernalis plc completes investment in its NCE development pipeline

Vernalis plc today announces the results from a Phase II proof-of-concept (POC) study of V158866, its fatty acid amide hydrolase (FAAH) inhibitor, which is being investigated as a treatment for neuropathic pain as a result of spinal cord injury.

Read more...

At a glance

More information on Vernalis and it's pipeline ...

FactsheetNov14 Company fact sheet

Comm thumbnail Explore the pipeline ...

Contact Vernalis

T: 0118 938 0000
F: 0118 938 0001

Contact information
Maps and directions
Contact form